NORTHWEST BIOTHERA COM USD0.001 (NWBO)

0.22
0.01 3.26
OTC
Prev Close 0.21
Open 0.22
Day Low/High 0.21 / 0.23
52 Wk Low/High 0.14 / 0.98
Volume 1.63M
Exchange OTC
Shares Outstanding 295.25B
Market Cap 55.36M
Div & Yield N.A. (N.A)

Latest News

Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today

Updates to Include Both DCVax®-L Phase III Trial and DCVax®-Direct Phase I/II Trial

Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K

Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K

Imagine a derailed freight train carrying dumpsters on fire. That's an accurate description of the Northwest Bio 10-K filed Monday night.

Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse

Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse

Northwest's inability to resolve the problems that froze the DCVax-L clinical trial -- and management's refusal to offer a public explanation for why it happened -- triggered the company's collapse.

Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

Northwest Biotherapeutics, a regular visitor to the capital markets, has negotiated a note payment schedule with Whitebox Advisors.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.

Short of Cash, Northwest Bio Flirts With Insolvency

Short of Cash, Northwest Bio Flirts With Insolvency

The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses.

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stocks.

Northwest Bio Blames Short Sellers, Not Warning From Expert Doctor, for Stock Plunge

Northwest Bio Blames Short Sellers, Not Warning From Expert Doctor, for Stock Plunge

Frank comments and a warning from a doctor supervising pivotal brain cancer vaccine study for Northwest Bio are likely cause of sharp slide in stock price.

First Week of NWBO March 18th Options Trading

First Week of NWBO March 18th Options Trading

Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the March 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new March 18th contracts and identified the following put contract of particular interest.

Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics

Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics

TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.

Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio

Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Northwest Bio Bothers British Bestie for Bounteous Bucks

Northwest Bio Bothers British Bestie for Bounteous Bucks

British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.

Interesting NWBO Put And Call Options For December 18th

Interesting NWBO Put And Call Options For December 18th

Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new December 18th contracts and identified one put and one call contract of particular interest.

Northwest Biotherapeutics is Now Oversold (NWBO)

Northwest Biotherapeutics is Now Oversold (NWBO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting NWBO Call Options For November 20th

Interesting NWBO Call Options For November 20th

Investors in Northwest Biotherapeutics Inc saw new options begin trading this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new November 20th contracts and identified the following call contract of particular interest.

Northwest Bio CEO: Brain Tumor Vaccine Study Enrollment Still Suspended

Northwest Bio CEO: Brain Tumor Vaccine Study Enrollment Still Suspended

Slightly more than 300 out of a required 348 brain tumor patients are currently enrolled in Northwest Bio's DCVax-L phase III study.

January 2018 Options Now Available For Northwest Biotherapeutics

January 2018 Options Now Available For Northwest Biotherapeutics

Investors in Northwest Biotherapeutics Inc saw new options begin trading today, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 858 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ALERT: Rosen Law Firm Reminds Northwest Biotherapeutics, Inc. Investors Of Important Class Action Deadline

ALERT: Rosen Law Firm Reminds Northwest Biotherapeutics, Inc. Investors Of Important Class Action Deadline

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Northwest Biotherapeutics, Inc.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Northwest Biotherapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Northwest Biotherapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of...